Approximately 800 patients per year are expected to benefit from today’s extended Pharmaceutical Benefits Scheme (PBS) listing of Xeloda® (capecitabine).
The treatment is now available on the PBS for patients with advanced bowel cancer – stage III (Dukes C) - in combination with another chemotherapy, oxaliplatin. The combination therapy is known as XELOX.
Julien Wiggins, chief executive of Bowel Cancer Australia said the extended PBS listing would be a financial relief to those who are facing numerous challenges in their battle against this disease.
“Treatments for advanced cancer are not just about the time given to that person, it’s what the time enables that person to do,” he added. “This listing means people aren’t wasting precious time worrying about what it costs to stay alive.”
For further information on bowel cancer treatments visit Bowel Cancer: Putting together your treatment plan - Surgery & Treatment.